To the best of our knowledge, this is the first report to investigate the intrinsic impacts of the PD-L1 expression status on postoperative recurrence among EGFR-mutated lung adenocarcinomas with a specific emphasis on stage-related outcomes. This evidence concerns the gene EGFR and lung adenocarcinoma.